CD19-directed Cytolytic Antibody class drugs

1 result
  • uplizna

    (Inebilizumab)
    Horizon Therapeutics USA, Inc.
    UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with anti-aquaporin-4 (AQP4) antibody positivity and for immunoglobulin G4-related disease (IgG4-RD) in adults.